Literature DB >> 21140159

Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.

Funda Gode1, Cigdem Karagoz, Cemal Posaci, Bahadir Saatli, Didem Uysal, Mustafa Secil, Bahri Akdeniz.   

Abstract

PURPOSE: We aimed to evaluate the alteration of cardiovascular and metabolic risk parameters of polycystic ovary syndrome (PCOS) patients after a 6-month treatment with an oral contraceptive (OC) containing cyproterone acetate (CPA).
METHODS: Forty women with PCOS were evaluated at baseline and after treatment with an OC. Carotid intima-media thickness (CIMT), brachial artery flow-mediated dilatation (FMD), nitrate-mediated dilatation (NMD), high sensitive (hs)-CRP, lipid levels, index of glucose sensitivity, and homeostasis model assessment of insulin resistance index (HOMA) were assessed.
RESULTS: Mean CIMT was significantly elevated (0.03 ± 0.01 mm) (p < 0.05). There was a tendency of reduction in FMD, which was significant among overweight patients (p < 0.05). Total cholesterol, low-density lipid (LDL), and triglyceride levels were significantly elevated (p < 0.05).
CONCLUSION: CIMT as an indicator of early atherosclerosis and FMD as a finding of endothelial dysfunction seem to be deteriorated especially in overweight PCOS patients who were prescribed to OC containing cyproterone acetate for 6 months.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21140159     DOI: 10.1007/s00404-010-1790-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women.

Authors:  Oluwole Adeyemi Babatunde; Swann Arp Adams; Samantha Truman; Erica Sercy; Angela E Murphy; Samira Khan; Thomas G Hurley; Michael D Wirth; Seul Ki Choi; Hiluv Johnson; James R Hebert
Journal:  Women Health       Date:  2020-04-05

Review 2.  The metabolic effects of drugs used for the treatment of polycystic ovary syndrome.

Authors:  Melia Karaköse; Erman Cakal; Kubilay Ertan; Tuncay Delibaşı
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-09-01

Review 3.  Energy metabolism and fertility: a balance preserved for female health.

Authors:  Sara Della Torre; Valeria Benedusi; Roberta Fontana; Adriana Maggi
Journal:  Nat Rev Endocrinol       Date:  2013-10-22       Impact factor: 43.330

4.  [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].

Authors:  Jun Zhang; Mi Su; Liangzhi Xu; Zhilan Yang; Weiyao Yin; Ying Nie; Xiaoyong Qiao; Ran Cheng; Yaxian Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

Review 5.  Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.

Authors:  Krystallenia I Alexandraki; Eleni A Kandaraki; Kalliopi-Anna Poulia; Christina Piperi; Eirini Papadimitriou; Theodoros G Papaioannou
Journal:  touchREV Endocrinol       Date:  2021-04-28

6.  Hyperinsulinaemic androgen excess in adolescent girls.

Authors:  Lourdes Ibáñez; Ken K Ong; Abel López-Bermejo; David B Dunger; Francis de Zegher
Journal:  Nat Rev Endocrinol       Date:  2014-04-29       Impact factor: 43.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.